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Introduction
The use of osseointegrated implants in the rehabilitation of the 
stomatognathic system is an increasingly more frequent procedure with 
a very predictable prognosis. However, the success of this technique is 
not the mere achievement of the osseointegration of the implant in the 
osseous bed. The ultimate goal must be the restitution of the missing 
teeth, through the placement of implants in anatomically appropriate 
positions in order to achieve a good aesthetic and functional result 
in the long term [1]. This result will depend, in large measure, on the 
volume of alveolar bone remaining. The loss of volume that the alveolar 
ridge experiences will vary depending on the time elapsed since the loss 
of the teeth, the cause of such loss, the previous treatments that were 
carried out, as well as the patients' intercurrent system factors [2,3]. 
The loss of teeth leads to atrophy of the alveolar bone, and many 
times we will face some major technical challenges when placing the 
implants in the most appropriate positions. Lack of bone volume, 
coupled with a low quality of the remaining bone, especially in the 
back sections of the jaw and mandible, forces us to resort to techniques 
that allow us to increase the volume, both in width and height, and 
if possible, the quality of the remaining bone, with the purpose of 
achieving the desired aesthetic and functional results [3].
Numerous surgical techniques have been developed for the 
reconstruction of the alveolar ridge and in these techniques various 
graft materials are used, all of which have advantages and disadvantages. 
Given that thus far no technique has been described that could be 
considered ideal and suitable for all circumstances, the surgeon must 
select and use the technique and graft material that allow for the best 
implant insertion in each particular case [4]. The materials that we can 
use as graft material can have diverse origins, which in turn condition 
their different properties and behaviors. Depending on their ability to 
interact with the surrounding bone, they can be classified as bioinert 
or bioactive materials. Bioactive materials are capable of stimulating 
the formation of bone tissue, by directly joining itself to the bone, thus 
forming a strong and unique interface of bone-biomaterial [4]. Graft 
material, on the other hand, should be biocompatible and it should be 
reabsorbed in order to be integrated into the neoformed bone, which 
is structurally similar to bone, osteoconductive and if possible also, 
osteoinductive and osteogenic (Table 1) [5,6]. When we act on the bone 
regeneration process we must also take its structure into consideration. 
We know that bone tissue is porous and depending on the size and 
the interconnection of the pores, it allows for vascularization, the 
diffusion of nutrients, and ultimately the growth of the tissue. It is this 
type of architecture and its composition that allows for the migration 
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Abstract
Oral implantology is a common procedure in dentistry, especially for fully or partially edentulous patients. The 
implants must be placed in the best location from both the aesthetic and functional point of view. Because of this it is 
increasingly more frequent to resort to regeneration techniques that use substitutes of the bone itself, in order to be able 
to insert the implants in the most appropriate location. 
Material and Methodology: A review was performed on the literature from the last ten years based on the following 
search limitations: “graft materials", "allograft", "xenograft", "autologous graft” and "dentistry”. 
Results: 241 works were obtained that after reading their respective summaries, they were reduced to 38, and 9 
previous works were included in order to summarize the concepts. 
Discussion: Autologous grafts are the "gold standard" of the bone regeneration. They have obvious advantages, 
but they also have drawbacks. This is why allogeneic and xenogeneic tissues are used. The former because of their 
clear similarity with the recipient's tissue and the latter due to their wide availability. Given that these grafts also have 
drawbacks, the industry has developed synthetic materials that have properties similar to those of human bone tissue. 
However, as of today, the ideal material to substitute human bone has not yet been found. In recent years the tendency 
has been to combine these synthetic materials with the patient's own bone, which is extracted during drilling in implant 
placement, with bone marrow aspiration, or with bone morphogenetic proteins. Thus the intention is to equip these 
substances with the osteogenic capacity. 
Conclusions: There is currently no ideal graft material, with the exception of those materials that come directly 
from the patient. We hope that in the coming years we will have products that will allow us to perform rehabilitations with 
better results and provide a better quality of life for our patients, especially those who have more complex situations to 
resolve, like the patients that are operated on for head and neck cancer.
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of the cells of adhesion, their proliferation and differentiation, thus 
contributing to the bone formation and its repair and regeneration [7].
The objective of the present study is to review the different graft 
materials that we can use in oral surgery with the aim of increasing or 
remodeling the bone volume in order to place implants. 
Material and Methodology
Search strategy
The PubMed database was searched by using the keywords “graft 
materials”, “allograft”, “xenograft”, “autologous graft" and "dentistry".
Selection and inclusion criteria
The first search with a span of up to ten years provided us with 
241 works. After reading their abstracts we included 47 of them and 
9 previous studies that were relevant to this revision: graft materials 
AND allograft AND dentistry: 91; graft materials AND xenograft 
AND dentistry: 31; and graft materials AND autologous graft AND 
dentistry: 119.
Discussion
Below we will review the most relevant aspects found in the 
literature with regard to the autologous grafts, allogeneic grafts, 
xenografts, alloplastic grafts and bone morphogenetic proteins.
Autologous grafts
The current reference standard in bone grafts is the autograft, with 
tissue obtained from the patient himself/herself, which is called an 
autologous graft (Table 2). This material can be obtained from donor 
areas near the one on which we are going to intervene, fundamentally 
the chin, the retromolar space and the ascending ramus of the mandible. 
It can also be obtained from distant areas such as the iliac crest or 
the cranial vault, which can cause a less comfortable postoperative 
experience for the patient (Figure 1). From the intraoral donor sites we 
are able to obtain a block of monocortical bone tissue, that if necessary, 
we will be able to divide. If what we need is a particulate tissue, it would 
be best to resort to the upper maxillary tuberosity area by using a 
trephine or a chisel. A true fact is that many times the tissue that we 
are able to obtain from the donor sites is insufficient for the needs of 
Osteoconduction
It is the property through which the bone graft material serves as scaffolding for the growth of new bone. The osteoblasts move from the margins of the defect that we 
want to repair, using the bone graft material as a framework through which it can diffuse and generate new bone, they will continue to incorporate the graft into this new 
bone, until it completely disappears. All bone graft material must at least be osteoconductive.
Osteoinduction
This is the stimulating capacity of the osteoprogenitor cells so that they differentiate into osteoblasts. By promoting the formation of new osteoblasts, faster integration 
of the graft is achieved. This property depends on the bone morphogenetic proteins (BMP) and the osteogenic proteins (collagen, osteonectin, osteopontin and bone 
sialoprotein) present in the extracellular matrix. This property is that which allows the bone to repair its fractures and to regenerate itself on its own.
Osteogenesis
It is the production of bone. A material is osteogenic when it has the intrinsic capacity to stimulate the formation of new bone. This is only possible when there are stem 
cells or vital osteoblasts in the graft material that we put in place.
Table 1: Concepts of osteoconduction, osteoinduction and osteogenesis [5,6].
AUTOLOGOUS MATERIALS
INTRAORAL ORIGIN EXTRAORAL ORIGIN
CHIN ILIAC CREST
MANDIBULAR RAMUS FIBULA
MAXILLARY TUBEROSITY CRANIAL VAULT
EXOSTOSIS RIBS
BIOLOGICAL DRILLING TIBIA
ALLOGENEIC MATERIALS
FRESH
FROZEN
FREEZE-DRIED
DEMINERALIZED FREEZE-DRIED
XENOGRAFTS
BOVINE
PORCINE
EQUINE
ALLOPLASTIC MATERIALS
CALCIUM SULPHATE 
CALCIUM PHOSPHATE
BETA-CALCIUM TRIPHOSPHATE
CORAL
HYDROXYAPATITE
CERAMICS
BIOACTIVE CRYSTALS
SYNTHETIC POLYMERS
COLLAGEN MATRICES
COMPOSITES
BONE MORPHOGENETIC PROTEINS
Table 2: Materials available to regenerate bone in oral surgery.
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the receptor site. Inorder to try to solve this problem, techniques have 
been developed such as the RIA system (Reamer/Irrigator/Aspirator), 
which has been designed to obtain bone tissue and bone marrow as well 
as eliminate the necrotic and/or infected bone tissue. The tissue that 
we are going to graft is an osteoconductive, osteoinductive (it contains 
growth factors) and osteogenic material, which means that it contains 
living cells that will be transferred to the recipient bed, provided that 
the time between the extraction and the placement does not exceed 
two hours and it is kept in an isotonic saline solution [8]. If we process 
the obtained tissue in order to transform it into small particles, we will 
destroy a significant percentage of the living cells, therefore reducing its 
osteogenic capacity [9]. Another aspect to consider is that the tissue is 
not antigenic. 
Autologous grafts can be derived from cortical bone, medullary 
bone, or a mixture of both. Cortical grafts are fundamentally 
osteoconductive and grant greater structural support. The spongy ones 
have greater cellularity, and therefore are more osteogenic, although 
they confer lesser resistance [10]. 
The surgeon must consider the use of autologous bone as graft 
material as a first option, but if this is not possible he/she must then 
search for alternative materials. In this case the most logical option 
would be to resort to the tissue that is most similar to the autologous 
bone, that being bones tissue from the same species, i.e. an allograft.
Allogeneic grafts
According to Russell and Leighton allografts represent 35% of the 
bone grafts that are carried out [11]. This type of transplant is being 
performed 25 times more than kidney transplants and 100 times more 
than heart transplants. This kind of material is closely monitored 
to ensure maximum safety with respect to its use. The control and 
monitoring in Spain correspond to the National Transplant Organization 
(Organización Nacional de Transplantes, ONT) [12] and in the USA to 
the American Association of Tissue Banks (AATB). Both follow the 
norms of the Center for Biologics Evaluation and Research (CBER) 
[13], an agency created under the U.S. Food and Drug Administration 
(FDA). These organizations require the tissue banks to comply with 
strict regulations with regard to the selection of donors, protocols 
for obtaining tissues, and tissue treatments, in order to minimize the 
possibility of disease transmission [14]. It is therefore necessary, that 
if we use this type of material we must know its provenance and if the 
distributor obtains it from a duly authorized tissue bank. Although the 
bone tissue could come from living donors, it is not usually the case and 
most commonly it comes from donors who have died.
Allografts (Figures 2 and 3) are available in multiple presentations. 
Figure 1: Reconstruction of the alveolar crest with an autologous graft.
Figure 2: Reconstruction of the alveolar crest with an allogeneic graft.
Figure 3: Post-extraction preservation of the alveolar ridge with an allogeneic 
graft. Results after three months.
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They are generally used in our field in a particulate form, either in 
cortical bone, spongy bone, or a mixture of both and also in the form 
of blocks. The properties of the allografts are limited by the processes of 
preparation and sterilization that they undergo [15]. These procedures 
are aimed at reducing the antigenicity of the graft so that it doesn't 
trigger a graft-versus-host reaction, and to eliminate the risk of disease 
transmission. The risk of disease transmission, although theoretically 
possible, is described as less than the risk that exists in a blood 
transfusion [6,16-19].
Tissue banks act on three levels to ensure the safety of the products 
that they distribute. First of all, they control the selection of donors, 
so that they don't use tissue from high-risk donors. Once the donor is 
accepted, they proceed to perform a battery of serological tests in order 
to rule out communicable diseases. If the serological results are correct, 
they proceed to carrying out cultures of the tissue in order to determine 
the bacterial load. If the results show a high degree of contamination, 
the tissue will be rejected. Finally, that tissue will undergo an additional 
process of sterilization in order to minimize the maximum risk [19,20]. 
Several protocols for treatment and subsequent sterilization have 
been described, usually through gamma rays, such as BioCleanse®, 
Tutoplast® or Clearant®, that are able to reduce the risk of infection 
to 1/106. For the specific case of HIV, the risk can be reduced to 1 in 
8,000,000, much lower than the risk of a blood transfusion, which is 
1/450,000. From the technical point of view, it has been achieved by 
applying certain radioprotectors to tissues, they can be irradiated under 
certain conditions with a dose of 50 kGy and there is no reduction in 
the structural properties of the tissue [17,21]. In spite of all of this, the 
risk of "zero" does not exist and some cases of disease transmission 
from donor to recipient have been reported [21-24]. While this is true, 
companies such as Tutogen Medical GmbH or RTI Surgical™ (Berlin, 
Germany) that have been distributing these kinds of grafts for over 30 
years, and with millions of surgical procedures performed with their 
products, do not have any documented case of disease transmission to 
any recipient [24].
The structural properties of the tissue can be affected by the processes 
that it undergoes. Depending on their method of conservation the 
allografts may be fresh, frozen or freeze-dried (Table 3). Fresh allografts 
are highly antigenic and have little time available for the purposes of 
carrying out serological tests and detecting possible diseases from 
the donor, therefore they are no longer used. The frozen allografts 
will induce less of an antigenic response than the fresh ones; their 
biomechanical properties are well preserved. Their storage time may 
be up to one year if they are preserved at -20°C and up to 5 years if we 
keep them at temperatures of -70°C. The freeze-dried preparations are 
even less antigenic and may be stored indefinitely at room temperature, 
although they are given an expiration date of 5 years [18]. 
A somewhat different from of the allograft is the Demineralized 
Bone Matrix (DBM). It is obtained from cortical bone that undergoes 
a decalcification process. The cells and minerals are removed from the 
tissue by subjecting it to an acid solution. Initially a solution of 0.5N of 
HCl was used for this purpose. Once it was processed, no viable cells 
were found in the tissue, and therefore by definition this product would 
be an aloimplant [25]. 
On the other hand, the activity of the growth factors varies 
depending on the tissue bank that it comes from, and evens the batch. 
Although it can have a certain amount of potential for osteoinduction 
due to the growth factors that it presents, it essentially behaves as an 
osteoconductor [16,18,26]. It is used for the filling in of bone defects 
that affect one or two walls. It can also be used as an autograft expander 
in order to obtain greater volume. Its use in situations that involve load 
support is contraindicated because it will collapse since it doesn't have 
sufficient structural rigidity [13,23]. 
Xenografts
The FDA defines a xenotransplant as the use of living cells, tissues or 
organs from an animal, non-human source, that are transplanted into a 
human being, or used in ex vivo contact with human bodily fluids, cells, 
tissues or organs, that will later be placed in a human [27,28] (Figure 
4). In dentistry the use of graft materials from bones of bovine origin 
is very common. In the last few decades the bovine bone has become 
a common source for the preparation of human bone substitutes, since 
these bones have a good osteoconductive capacity. The non-human 
Origen Osteoconduction Osteoinduction Osteogenesis Structural Resistance Antigenicity
Risk of Disease 
Transmission
Autologous 
Materials
Cortical Natural +++ ++ ++ +++ - -
Spongy Natural +++ +++ +++ - - -
Allogeneic 
Materials
Fresh Natural +++ ++ + +++ *** ***
Frozen Natural +++ + - +++ ** *
Freeze-Dried Natural +++ + - ++ * *
Demineralized Natural + ++ - - - *
Xenografts Bovine / Porcine / Equine Natural +++ - - +++ * *
Alloplastic 
Materials
Calcium Phosphate Synthetic + - - - - -
Calcium Sulphate Synthetic +  - - - - -
Beta-Calcium 
Triphosphate Synthetic +++ - - - - -
Coral Natural +++ - - ++ - -
Hydroxyapatite Synthetic + - - - - -
Collagen Natural ++ - - - - -
Synthetic Polymers Synthetic ++ - - ++ - -
Bioactive Crystals Synthetic ++ - - ++ - -
Bone Morphogenetic 
Proteins Synthetic - +++ - - - -
Score: - (none), + (low), ++ (medium), +++ (excellent)  Score: - (none), * (low), *** (high) 
Table 3: Different materials used as bone graft in oral surgery and their most important features.
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origin of these materials may generate some aversion due to the risk that 
they might produce some type of disease transmission from the donor 
to the recipient, as can happen in the case of allografts. This concern 
is clearer after the episodes of the Bovine Spongiform Encephalopathy 
(BSE), which made the industry increase their efforts with respect to 
obtaining sanitarily safe materials [29].
During the manufacturing process the bovine bone undergoes 
thermal processes to eliminate the proteins present in the tissue, which 
may reach, in some cases, temperatures close to 1000ºC for several 
hours. This produces ceramming of the tissue which alters its porosity, 
therefore losing part of its osteoconductive capacity. Additionally this 
ceramming can hinder the proper reabsorption of the material and the 
integration into the neoformed bone [29]. These tissues are also subject 
to the action of a strong alkaline solution, NaOH 1-2molar solution, for 
two hours, which results in a decrease in the risk of infectivity of the 
tissue to a minimum of 1/105. BSE prions, if they were to exist, could be 
considered practically inactivated. Additionally, the tissue will undergo 
a treatment with organic solvents which will give rise to the removal 
of fat. These solvents will destroy the three-dimensional structure of 
proteins due to the hydrophobic nature of the organic solvents [29,30] 
The distribution of xenografts in the USA is also controlled by the 
FDA and they are considered and regulated as medical devices [31]. In 
Europe, in order to minimize the risk of BSE transmission to humans 
through these products, the German Federal Ministry of Health 
published health requirements that the products derived from bovine, 
caprine, or sheep tissue must meet [32,33].
Xenografts are an efficient material and are regarded as sanitarily 
safe products. However we must comment on the work of Kim who 
carry out a comprehensive review in which they identify studies 
published about the presence and infectivity of the BSE prions in 
bovine bone, the inactivation of these prions during the process of 
conditioning and the sterilization of the products for bone grafts 
[34]. The authors conclude that these biomaterials involve a risk of 
transmission of BSE prions to the patients, although the risk cannot 
be quantified based on the information that is currently available. Even 
when this risk exists, the strict controls in the selection of the donor 
animals and the processes that the tissues must undergo have ensured 
that there are no documented cases of transmission to the recipients.
Alloplastic grafts
Finally, among the grafts, we have the strictly synthetic materials 
left to comment on, these constitute the alloplastic grafts (Figure 5). 
They are osteoconductors and they can be bioactive or inert. They are 
available in multiple presentations. While bioactive materials chemically 
interact with the bone of the recipient, and thus are able to induce bone 
neoformation, the inert materials don't join in any way to the recipient 
bone and they only establish intimate contact between them that will 
allow for the transmission of forces [7]. We have various types of materials 
available depending on their composition: Compounds of calcium 
phosphate, calcium sulfate, coral, Hydroxyapatite, collagen matrices, 
synthetic polymers, bioactive crystals and calcium triphosphate, in 
addition to the osteoinductive proteins, which, although they are a 
synthetic product, their mechanism of action is completely different 
[35]. These materials have some obvious advantages since they cannot 
transmit diseases, and in principle, they have unlimited availability.
During the manufacturing process, they can be modified to 
be particle-sized, pore-sized, to have adequate porousness, contact 
area, and a chemical structure that makes the material an ideal 
osteoconductor. Their structural properties are high but they are fragile 
materials with little resistance to traction, and therefore they cannot be 
used in areas subject to loads of weight. Their mechanical properties 
are closely correlated to porosity and pore size. The larger the size of the 
pore, the better cell permeability they will have, however there is less 
structural resistance. The manufacturing process will also determine 
its reabsorption time. The time that it takes to reabsorb the synthetic 
material is important, while an adequate volume is maintained, this 
material may be able to be substituted by bone, if disappears too quickly, 
there won't be enough time for the bone to be formed [35,36].
If we consider the different graft products (Table 2), the use of 
materials made up of calcium sulfate began to appear in dentistry as 
early as the 70’s. They were developed as bone substitution materials 
because of their similarity in composition to that of bone. This similarity 
grants them similar behavior to that of human bone. They are used in 
cement forms in an aqueous solution or as titanium surface coatings. 
They can be used as an abrasive instead of alumina [7]. When they are 
used in cement forms, they can be applied directly to the bone defect 
or through the use of a syringe. Once placed, the hardening process 
of the material occurs in situ, due to the precipitation of the calcium 
phosphate particles. Not all of the materials of this type can be used 
in the oral cavity, since some of them quickly dissolve in an aqueous 
medium [36]. Tricalcium phosphate, in its beta phase, is marketed 
in the form of granules and is reabsorbed almost in its entirety in a 
few months, at the same time that it is forming new bone in whose 
metabolism it does not interfere. It is a biocompatible material that 
is obtained, just like Hydroxyapatite, through a heat treatment [37]. 
Hydroxyapatite can be obtained naturally from the exoskeletons of 
the coral reef. Through a variety of processes, such as chemical and 
thermal ones, the coral becomes Hydroxyapatite. The porous structure 
of the coral remains intact, providing an ideal matrix through which 
new bone tissue can grow. It is possible to obtain it through industrial 
processes and there are no differences in the properties of one or the 
other [37]. Their process of reabsorption is much slower than that 
of calcium phosphate [38]. Ceramics are made up of Hydroxyapatite 
crystals and beta Tricalcium phosphate. They are used as a framework 
to facilitate bone regeneration and they are good osteoconductors. 
Osteoid substance is deposited directly on the ceramic surface in 
order to continue forming new bone that will be remodeled by the 
Figure 4: Reconstruction of the alveolar crest with a particulate xenograft and 
titanium mesh.
Figure 5: Particulate graft of hydroxyapatite with a collagen membrane and 
situation after the three months.
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action of osteoblasts and osteoclasts [39]. The bioactive crystals are 
amorphous materials, made up of oxides and silica. They constitute a 
three-dimensional porous network which promotes the growth of bone 
tissue. The synthetic polymers used as graft materials are polylactic acid 
and polyglycolic acid. The latter is reabsorbed more quickly than the 
former. To improve their features of resistance and radiopacity, they 
are mixed with calcium phosphate [40]. The search for the ideal bone 
substitute has led to the development of new materials that are made up 
of several components and are called composites. They generally consist 
of an osteoconductive matrix that will promote the growth of new bone, 
osteoinductive proteins that induce the differentiation of stem cells and 
osteoblasts, or their precursors, that will lead to the formation of new 
bone [36].
Currently the option of using these materials as containers or 
carriers of various drugs is also being studied. These drugs include 
antibiotics, growth factors or the same bone morphogenetic proteins, 
which would make these materials osteogenic [41-43].
Morphogenetic proteins (BMP or rhBMP)
They are obtained through recombinant DNA techniques that allow 
a bacterium to produce a human protein. RhBMP-2 was approved by 
the FDA for its use in certain surgeries of the spine. In March of 2007 
authorization was obtained to use it in sinus lifting techniques, post-
extraction preservation of the dental alveolus, and augmentation of the 
alveolar crest [44]. It is presented in the form of a freeze-dried powder 
that must be reconstituted and it is applied after being soaked in a 
reabsorbable collagen sponge. The most effective product concentration 
is 1.5 mg/cc. The sponge keeps the protein in the desired place and it 
provides a support so that the new bone can grow. While the graft is 
progressing, the sponge is being reabsorbed and it is replaced by the 
neoformed bone. Wikesjo et al. [45] posed the hypothesis that if dental 
implants coated with this protein are used, they could stimulate local 
bone formation and improve the osteointegration in areas of poor bone 
quality or areas where it is necessary to perform augmentation of the 
alveolar crest. In the study that they carried out, they obtained good 
results [45]. Very recent aspects on these issues have been addressed by 
Díaz-Sánchez et al. and Kühl et al. [46,47].
Finally we can state that the ideal substitute of human bone in oral 
surgery does not exist, and that the surgeon must choose the most 
appropriate material for each situation among the many materials that 
are available. We hope that with the investigations that are under way, 
in the next few years we will have a synthetic material that possesses 
all of the characteristics of human bone and that allows us to eliminate 
all of the disadvantages that autologous and allogeneic grafts present.
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